About Napp

We’re in the business of bringing medicines to the NHS. It is work that deeply affects the lives of health providers and patients – and here at Napp we pride ourselves on doing it the right way.

The UK is not just our market, it’s our home. We’re a privately owned UK company with a strong track record in bringing high quality, innovative medicines to UK healthcare professionals and their patients.

Please visit us regularly to find the latest information.

Healthcare Professional holding hands of a patient

Therapy Areas

  • Biosimilars
  • Cardiovascular
  • Diabetes
  • Oncology
  • Pain Management & Supportive Care
  • Respiratory

Important Safety Information

Therapy Areas

Important Safety Information

Events & Resources

  • Upcoming Events
  • On Demand
  • Articles
  • Other Resources

On Demand

Recent Data Transforming the Management of Kidney Disease in Patients with Type 2 Diabetes

Recent Data Transforming the Management of Kidney Disease in Patients with Type 2 Diabetes

T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.

In this video, Dr. Davies will discuss the unmet needs of slowing down kidney disease progression in type 2 diabetes, and the therapeutic innovation with data on the SGLT2 inhibitors.

Dr. Sarah Davies

MBBCh (hons), FRCP, MRCGP, PGDip

Clinical Director for Diabetes in Primary Care

for Cardiff and Vale University Health Board

  • English
  • 0:10:21
  • Diabetes
  • webinar
  • T2DM Expert Talks, Promotional Content
Recent Data Transforming the Management of Kidney Disease in Patients with Type 2 Diabetes

Recent Data Transforming the Management of Kidney Disease in Patients with Type 2 Diabetes

T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.

In this video, Dr. Wheeler will share his thoughts on how the recent data from SGLT2 inhibitors is driving the therapeutic innovation in the management of kidney disease in patients with type 2 diabetes.

Dr. David Wheeler

Dr. David Wheeler, MBChB, MRCP, MD, FRCGP

Professor of Kidney Medicine at University College London and Honorary

Consultant Nephrologist at the Royal Free London NHS Foundation Trust, UK

  • English
  • 0:05:17
  • Diabetes
  • webinar
  • T2DM Expert Talks, Promotional Content
A video snapshot

Perspectives on Diabetes & CKD by Healthcare Professional

This non-promotional video from Jane Diggle covers her perspectives on diabetes and chronic kidney disease and why it’s such an important topic for people with type 2 diabetes.

Jane Diggle

Jane Diggle,

Practice nurse with specialist interest

in diabetes, West Yorkshire

  • English
  • 00:08:44
  • Diabetes
  • webinar
  • Non-promotional Content

Importance of early screening and diagnosis of CKD in T2DM

This paper reviews the burden of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) and describes how clinicians can best utilise early screening and diagnosis together with renal protective therapies to improve patient outcomes.

Read More

Subgroup analysis of CREDENCE trial on the effects of canagliflozin on heart failure and CV death

In the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, canagliflozin demonstrated a risk reduction for hospitalisation for heart failure (HHF) or cardiovascular (CV) death by 31% (HR 0.69, 95% CI 0.57-0.83, P=0.0001). In this paper the authors explore the effect of canagliflozin on HHF/CV death stratifying the CREDENCE population according to different clinical characteristics.

Read More

Empagliflozin effects in patients with heart failure

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown reduction in hospitalisation for heart failure (HHF) and serious adverse renal events risks, beyond their glucose-lowering benefits. More specifically, patients with type 2 diabetes who received SGLT2 inhibitors in large-scale, randomised, placebo-controlled trials experienced a 30% to 35% lower risk of HHF compared with patients who received placebo, even though most of them did not have a history of heart failure at baseline.

Read More
Triple protection Info

Infographics

Triple Protection

Credence

Infographics

CREDENCE study

Pooled info

Infographics

Pooled Analysis of CREDENCE and CANVAS